Combined gemcitabine and S-1 chemotherapy for treatingunresectable cholangiocarcinoma
10.3760/cma.j.issn.1673-4904.2019.04.015
- VernacularTitle:吉西他滨联合S-1治疗不可切除的胆管癌的疗效观察
- Author:
Meiyue TANG
1
;
Wei CHEN
;
Siliang WANG
Author Information
1. 中国医科大学附属盛京医院肿瘤科
- Keywords:
Gemcitabine;
S-1;
Cholangiocarcinoma;
Comparative study
- From:
Chinese Journal of Postgraduates of Medicine
2019;42(4):352-355
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of the gemcitabine(GEM) plus S-1 in unresectable cholangiocarcinoma. Methods Forty-nine unresectable cholangiocarcinoma patients from January 2010 to June 2014 were randomly divided into two groups. The experimental group contained 25 patients treated with gemcitabine and S-1 and the control group contained 24 patients treated with gemcitabine and cisplatin. Results The experimental group′s release rate (RR) and disease control rate (DCR) was 36.0% (9/25) and 76.0% (19/25),the control group′s was 25.0(6/24) and 58.3% (14/25), and there were no statistically significant differences (P=0.403 and 0.187). One-year survival rate for the experimental and the control groups were 40.0% (8/25) and 29.2% (7/24), and there was no statistically significant difference (P=0.426). Median overall survival (OS) in the experimental and control groups was 13.0 and 12.3 months, and there was no statistically significant difference (χ2=0.273, P=0.602). The rate ofⅠ～Ⅱgrade of oral mucositis was more higher than that in the control group [25.0%(6/24) vs. 4.0% (1/25), P=0.036 ]. Conclusions Combination of GEM and S-1 provides a better OS and response rate, and is safer.
